BusinessMadrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASHBy Nasdaq OMXAug 1, 2017, 11:30 AM UTC
BusinessAmerican Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in SchizophreniaBy Nasdaq OMXJul 31, 2017, 12:30 PM UTC
BusinessOrganovo and UC San Diego Receive $1.7 Million Grant From National Institutes of Health to Study Liver DiseaseBy Nasdaq OMXJul 31, 2017, 12:05 PM UTC
BusinessRedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s DiseaseBy Nasdaq OMXJul 31, 2017, 12:01 PM UTC
BusinessMyriad to Announce Fiscal Fourth-Quarter 2017 Financial Results on August 8, 2017By Nasdaq OMXJul 28, 2017, 3:16 PM UTC
BusinessNewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod ProgramBy Nasdaq OMXJul 28, 2017, 12:00 PM UTC
BusinessKalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial ResultsBy Nasdaq OMXJul 27, 2017, 8:01 PM UTC
BusinessNewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802By Nasdaq OMXJul 27, 2017, 11:00 AM UTC
